DK0950657T3 - Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer - Google Patents

Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer

Info

Publication number
DK0950657T3
DK0950657T3 DK99302967T DK99302967T DK0950657T3 DK 0950657 T3 DK0950657 T3 DK 0950657T3 DK 99302967 T DK99302967 T DK 99302967T DK 99302967 T DK99302967 T DK 99302967T DK 0950657 T3 DK0950657 T3 DK 0950657T3
Authority
DK
Denmark
Prior art keywords
preparation
spla2 inhibitors
substituted carbazoles
carbazoles
substituted
Prior art date
Application number
DK99302967T
Other languages
Danish (da)
English (en)
Inventor
Nicholas James Bach
Jolie Anne Bastian
Gary Alan Hite
Edward David Mihelich
John Michael Morin Jr
Daniel Jon Sall
Robert Theodore Vasileff
Michael Dean Kinnick
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0950657T3 publication Critical patent/DK0950657T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99302967T 1998-04-17 1999-04-16 Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer DK0950657T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17
EP99302967A EP0950657B1 (de) 1998-04-17 1999-04-16 Substituierte Karbazole, Verfahren zu ihrer Herstellung und ihre Verwendung als sPLA2-Inhibitoren

Publications (1)

Publication Number Publication Date
DK0950657T3 true DK0950657T3 (da) 2004-11-22

Family

ID=22041763

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99302967T DK0950657T3 (da) 1998-04-17 1999-04-16 Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer

Country Status (30)

Country Link
EP (2) EP0950657B1 (de)
JP (2) JPH11322713A (de)
KR (2) KR19990083232A (de)
CN (1) CN1149193C (de)
AR (2) AR018186A1 (de)
AT (2) ATE271037T1 (de)
AU (2) AU753436B2 (de)
BR (2) BR9901279A (de)
CA (2) CA2269262A1 (de)
CO (2) CO5031247A1 (de)
CZ (2) CZ136999A3 (de)
DE (2) DE69917833T2 (de)
DK (1) DK0950657T3 (de)
DZ (1) DZ2769A1 (de)
EA (2) EA002816B1 (de)
ES (2) ES2226286T3 (de)
HU (2) HUP9901221A3 (de)
ID (2) ID23287A (de)
IL (2) IL129483A0 (de)
NO (2) NO314400B1 (de)
NZ (3) NZ335253A (de)
PE (2) PE20000432A1 (de)
PL (2) PL332565A1 (de)
PT (1) PT950657E (de)
SG (2) SG81977A1 (de)
SI (1) SI0950657T1 (de)
TR (2) TR199900843A2 (de)
TW (1) TWI238160B (de)
YU (2) YU19199A (de)
ZA (2) ZA992771B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009978A1 (en) * 1997-08-28 1999-03-04 Eli Lilly And Company Method for treatment of non-rheumatoid athritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
AU1940800A (en) * 1998-12-21 2000-07-12 Eli Lilly And Company Combination therapy for the treatment of sepsis
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
JP2003505372A (ja) * 1999-07-19 2003-02-12 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビター
ES2294003T3 (es) * 2000-06-29 2008-04-01 Anthera Pharmaceuticals, Inc. Remedios contra el cancer.
WO2002000257A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for alzheimer's disease
AU2001267825A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
WO2002005796A2 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
WO2002050034A2 (en) * 2000-12-18 2002-06-27 Eli Lilly And Company Tetracyclic carbazole derivates and their use as spla2 inhibitors
DE60218155D1 (de) 2001-03-28 2007-03-29 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (de) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Neue Tetrahydrocarbazolderivate als Liganden von G-Protein-gekoppelten Rezeptoren
WO2009119534A1 (ja) 2008-03-26 2009-10-01 第一三共株式会社 新規テトラヒドロイソキノリン誘導体
EP2282742A1 (de) 2008-04-09 2011-02-16 Infinity Pharmaceuticals, Inc. Inhibitoren von fettsäureamidhydrolase
US8580795B2 (en) 2009-01-22 2013-11-12 Orchid Chemicals & Pharmaceuticals Limited Heterocyclic compounds as phosphodiesterase inhibitors
US8541581B2 (en) 2009-04-07 2013-09-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8546564B2 (en) 2009-04-07 2013-10-01 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
MX361692B (es) 2010-02-03 2018-12-13 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
WO2014083113A1 (en) 2012-11-30 2014-06-05 Ge Healthcare Limited Crystallization process of tricyclic indole derivatives
CN104797559A (zh) * 2012-11-30 2015-07-22 通用电气健康护理有限公司 卤化锌介导的环化过程得到三环吲哚
WO2016116527A1 (de) * 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
WO1993001169A2 (en) * 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
DE69610793T2 (de) * 1995-06-23 2001-05-03 Eli Lilly And Co., Indianapolis 6-Subsitituierte-1,2,3,4-tetrahydro-9H-Carbazole und 7-substituierte-1OH-Cyclohepta(7,6-B)-Indole
EP0779271B1 (de) * 1995-12-13 2001-08-01 Eli Lilly And Company Naphthyl-Acetamide als sPLA2-Inhibitoren
PL332896A1 (en) * 1996-10-30 1999-10-25 Lilly Co Eli Substituted tricyclic compounds
CA2304482A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
CA2310250A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
KR100586761B1 (ko) 2006-06-08
SG81976A1 (en) 2001-07-24
AR018593A1 (es) 2001-11-28
NO314400B1 (no) 2003-03-17
DE69918590T2 (de) 2005-07-21
KR19990083233A (ko) 1999-11-25
NO991821L (no) 1999-10-18
NO991822L (no) 1999-10-18
PL332565A1 (en) 1999-10-25
HU9901220D0 (en) 1999-06-28
TR199900843A2 (xx) 2000-02-21
SG81977A1 (en) 2001-07-24
CO5011054A1 (es) 2001-02-28
CZ137099A3 (cs) 1999-11-17
HU9901221A (hu) 2000-04-28
CZ136999A3 (cs) 1999-11-17
PT950657E (pt) 2004-11-30
EA199900303A2 (ru) 1999-10-28
KR19990083232A (ko) 1999-11-25
IL129485A0 (en) 2000-02-29
NZ507564A (en) 2002-10-25
IL129483A0 (en) 2000-02-29
NO991822D0 (no) 1999-04-16
HU9901221D0 (en) 1999-06-28
ATE268756T1 (de) 2004-06-15
EP0950657A3 (de) 2001-08-16
HUP9901220A3 (en) 2001-11-28
CA2269246C (en) 2009-08-25
JP2000026416A (ja) 2000-01-25
ID23287A (id) 2000-04-05
ATE271037T1 (de) 2004-07-15
JPH11322713A (ja) 1999-11-24
PE20000432A1 (es) 2000-05-23
HU9901220A (hu) 2000-04-28
CN1253948A (zh) 2000-05-24
NO312240B1 (no) 2002-04-15
TR199900853A2 (xx) 1999-11-22
YU19199A (sh) 2002-08-12
DE69917833D1 (de) 2004-07-15
EA002347B1 (ru) 2002-04-25
PE20000476A1 (es) 2000-06-02
EA199900301A2 (ru) 1999-10-28
BR9901279A (pt) 2000-05-02
AU753547B2 (en) 2002-10-24
BR9902365A (pt) 2001-04-24
CA2269262A1 (en) 1999-10-17
JP4435330B2 (ja) 2010-03-17
HUP9901221A3 (en) 2001-11-28
EA199900303A3 (ru) 2000-04-24
AU753436B2 (en) 2002-10-17
NZ335253A (en) 2000-11-24
EP0952149A2 (de) 1999-10-27
NZ335251A (en) 2000-11-24
ZA992772B (en) 2002-07-16
TWI238160B (en) 2005-08-21
EA002816B1 (ru) 2002-10-31
EA199900301A3 (ru) 2000-04-24
TR199900853A3 (tr) 1999-11-22
CN1149193C (zh) 2004-05-12
YU18999A (sh) 2002-08-12
EP0952149A3 (de) 2001-08-16
NO991821D0 (no) 1999-04-16
DE69918590D1 (de) 2004-08-19
EP0950657B1 (de) 2004-07-14
ZA992771B (en) 2002-04-18
PL332566A1 (en) 1999-10-25
DZ2769A1 (fr) 2003-12-01
AR018186A1 (es) 2001-10-31
SI0950657T1 (en) 2005-02-28
CO5031247A1 (es) 2001-04-27
CA2269246A1 (en) 1999-10-17
ES2222663T3 (es) 2005-02-01
ES2226286T3 (es) 2005-03-16
AU2381999A (en) 1999-10-28
EP0950657A2 (de) 1999-10-20
AU2381799A (en) 1999-10-28
EP0952149B1 (de) 2004-06-09
ID23761A (id) 2000-05-11
DE69917833T2 (de) 2005-07-14

Similar Documents

Publication Publication Date Title
DK0950657T3 (da) Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer
DK1076657T3 (da) Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
NO20012058L (no) 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
NO20032229D0 (no) Fremgangsmåter for behandling av p38kinase-assosierte tilstander og pyrrolotriazin forbindelser nyttige som kinase inhibitorer
DK1202733T3 (da) 3(5)-amino-pyrazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO20011575L (no) Substituerte 3-cyanokinoliner som proteintyrosin-kinase- inhibitorer
NO20011574D0 (no) Substituerte 3-cyanokinoliner som proteintyrosin-kinsase- inhibitorer
NO20021239L (no) Pteridinoner som kinase-inhibitorer
DK1425014T3 (da) Diarylcycloalkylderivater, fremgangsmåde til deres fremstilling og deres anvendelse som PPAR-aktivatorer
DK1268431T3 (da) 3-Cyanoquinoliner, 3-cyano-1,6-naphthyridiner og 3-cyano-1,7-naphthyridiner som proteinkinaseinhibitorer
NO20015065L (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
NO20006029L (no) Pyrazolinderivater, deres fremstilling og anvendelse som legemidler
DK1330455T3 (da) Hidtil ukendte 7-azaindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
NO20015062D0 (no) Substituerte 3-cyano-[1.7],[1.5]og[1.8]-naftyridin- inhibitorer for tyrosin-kinaser
NO20040210L (no) Fenylacetamido-tiazolderivater, fremgangsmate for deres fremstilling og deres anvendelse som antitumormidler
DK0795547T3 (da) (Aminoalkyl- og acylaminoalkyl-oxy)benzyloxyquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse som bradyk
DK1068223T3 (da) Lipopeptidantibiotika-calciumsalte, fremgangsmåde til deres fremstilling og anvendelse
NO331195B1 (no) Fremgangsmate for fremstilling av halogen-substituerte monosulfider og deres hydroksymonosulfid-evkivalenter som mellomprodukter.
NO20013735L (no) Fremgangsmåte til fremstilling av di-iso-butaner, di-iso- butener og di-n-butener fra feltbutaner
DK1214302T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
NO20025884D0 (no) 2-aminotiazolinderivater og deres anvendelse som NO- syntaseinhibitorer
DK1086077T3 (da) Hidtil ukendte antiestrogener, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse
DK1341758T3 (da) Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme
NO20020308D0 (no) Fremgangsmåte for fremstilling av epothiolon B og derivater, såvel som mellomprodukter for fremgangsmåten